AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for amoxicillin; omeprazole magnesium; rifabutin and what is the scope of freedom to operate?
Amoxicillin; omeprazole magnesium; rifabutin
is the generic ingredient in one branded drug marketed by Redhill and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.Amoxicillin; omeprazole magnesium; rifabutin has thirty patent family members in twenty-five countries.
One supplier is listed for this compound.
Summary for AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN
| International Patents: | 30 |
| US Patents: | 7 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN
Generic Entry Date for AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN*:
Constraining patent/regulatory exclusivity:
GENERATING ANTIBIOTIC INCENTIVES NOW Dosage:
CAPSULE, DELAYED RELEASE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN
| Drug Class | Penicillin-class Antibacterial Proton Pump Inhibitor Rifamycin Antimycobacterial |
| Mechanism of Action | Cytochrome P450 2C19 Inhibitors Proton Pump Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN
US Patents and Regulatory Information for AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Redhill | TALICIA | amoxicillin; omeprazole magnesium; rifabutin | CAPSULE, DELAYED RELEASE;ORAL | 213004-001 | Nov 1, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Redhill | TALICIA | amoxicillin; omeprazole magnesium; rifabutin | CAPSULE, DELAYED RELEASE;ORAL | 213004-001 | Nov 1, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Redhill | TALICIA | amoxicillin; omeprazole magnesium; rifabutin | CAPSULE, DELAYED RELEASE;ORAL | 213004-001 | Nov 1, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Redhill | TALICIA | amoxicillin; omeprazole magnesium; rifabutin | CAPSULE, DELAYED RELEASE;ORAL | 213004-001 | Nov 1, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Redhill | TALICIA | amoxicillin; omeprazole magnesium; rifabutin | CAPSULE, DELAYED RELEASE;ORAL | 213004-001 | Nov 1, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Cyprus | 1122113 | ⤷ Sign Up | |
| Philippines | 12015501783 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI | ⤷ Sign Up |
| New Zealand | 711754 | Pharmaceutical compositions for the treatment of helicobacter pylori | ⤷ Sign Up |
| Hong Kong | 1217645 | 用於治療幽門螺桿菌的藥物組合物 (PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI) | ⤷ Sign Up |
| Croatia | P20191559 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
